Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

RAIN ONCOLOGY INC.

(RAIN)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-03 pm EST
9.750 USD   +0.21%
01/31Rain Oncology to Participate in the 2023 Guggenheim Healthcare Talks Oncology Day Conference
AQ
01/23Rain Oncology Inc. : Regulation FD Disclosure (form 8-K)
AQ
01/23Phase 1 Clinical Data of Milademetan Published in Journal of Clinical Oncology
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about RAIN ONCOLOGY INC.
01/31Rain Oncology to Participate in the 2023 Guggenheim Healthcare Talks Oncology Day Confe..
AQ
01/23Rain Oncology Inc. : Regulation FD Disclosure (form 8-K)
AQ
01/23Phase 1 Clinical Data of Milademetan Published in Journal of Clinical Oncology
AQ
01/23Rain Oncology Inc. Announces Phase 1 Clinical Data of Milademetan Publishes in Journal ..
CI
01/23Mizuho Starts Rain Oncology at Buy With $18 Price Target
MT
01/23Rain Oncology's Likely 'Positive Outcome' in Phase 3 Milademetan Study in Q1 Underpinni..
MT
01/11Transcript : Rain Therapeutics Inc. Presents at 41st Annual J.P. Morgan Healt..
CI
01/06Lifesci Capital Starts Rain Therapeutics at Outperform With $17 Price Target
MT
01/05EF Hutton Initiates Rain Therapeutics at Buy With $16 Price Target
MT
2022Rain Therapeutics Inc. will Change its Name to Rain Oncology Inc
CI
2022Rain Therapeutics Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, ..
AQ
2022Rain Therapeutics to Change Name to Rain Oncology
MT
2022Rain Therapeutics Inc. Announces Name Change to Rain Oncology Inc.
AQ
2022Rain Therapeutics to Participate in the 41st Annual J.P. Morgan Health Care Conference
AQ
2022Rain Therapeutics Inc.(NasdaqGS:RAIN) dropped from NASDA..
CI
2022Insider Buy: Rain Therapeutics
MT
2022Citigroup Adjusts Price Target on Rain Therapeutics to $29 From $30, Maintains Buy Rati..
MT
2022Rain Therapeutics Announces a Poster Presentation at the 2022 San Antonio Breast Cancer..
AQ
2022Rain Therapeutics to Participate in Piper Sandler's 34th Annual Healthcare Conference
AQ
2022Rain Therapeutics Announces an Oral Presentation at the Connective Tissue Oncology Soci..
AQ
2022Insider Buy: Rain Therapeutics
MT
2022Rain Therapeutics to Participate in H.C. Wainwright's 3rd Annual Precision Oncology Vir..
AQ
2022Rain Therapeutics Inc. : Results of Operations and Financial Condition (form 8-K)
AQ
2022Transcript : Rain Therapeutics Inc., Q3 2022 Earnings Call, Nov 10, 2022
CI
2022RAIN THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
AQ
2022Rain Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Pr..
AQ
2022Rain Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months E..
CI
2022Insider Buy: Rain Therapeutics
MT
2022Rain Therapeutics : Material Agreement - Form 8-K
PU
2022Rain Therapeutics Inc. : Entry into a Material Definitive Agreement, Financial Statements ..
AQ
2022Rain Therapeutics Prices $50 Million Offering; Shares Up
MT
2022Rain Therapeutics Inc. : Regulation FD Disclosure (form 8-K)
AQ
2022Rain Therapeutics Announces $50 Million Registered Offering of Common Stock
AQ
2022Rain Therapeutics Provides Interim Analysis of Phase 2 Basket Trial of Milademetan for ..
AQ
2022Rain Therapeutics Provides Interim Analysis of Phase 2 Basket Trial of Milademetan for ..
CI
2022Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Rece..
AQ
2022Rain Therapeutics Announces a Poster Presentation at the 34th EORTC/AACR/NCI Symposium
AQ
2022HC Wainwright Initiates Rain Therapeutics at Buy With $10 Price Target
MT
2022Transcript : Rain Therapeutics Inc. Presents at Citi's 17th Annual BioPharma ..
CI
2022Rain Therapeutics to Participate in Citi's 17th Annual BioPharma Conference
AQ
2022Transcript : Rain Therapeutics Inc., Q2 2022 Earnings Call, Aug 04, 2022
CI
2022RAIN THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
AQ
2022Rain Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months E..
CI
2022Rain Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent P..
AQ
2022Rain Therapeutics Completes Enrollment in Phase 3 Cancer Treatment Trial Five Months Ah..
MT
2022Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milade..
AQ
2022Rain Therapeutics Inc. Announces Completion of Enrollment in Phase 3 MANTRA Trial for ..
CI
2022Rain Therapeutics to Report Second Quarter 2022 Financial Results and Highlights of Rec..
AQ
2022Rain Therapeutics Inc.(NasdaqGS:RAIN) dropped from Russe..
CI
2022Rain Therapeutics Inc.(NasdaqGS:RAIN) dropped from Russe..
CI
2022Rain Therapeutics Inc.(NasdaqGS:RAIN) dropped from Russe..
CI
2022Rain Therapeutics Inc.(NasdaqGS:RAIN) dropped from Russe..
CI
2022Rain Therapeutics Inc.(NasdaqGS:RAIN) dropped from Russe..
CI
2022Rain Therapeutics Inc.(NasdaqGS:RAIN) dropped from Russe..
CI
2022Rain Therapeutics Inc.(NasdaqGS:RAIN) dropped from Russe..
CI
2022Rain Therapeutics Inc.(NasdaqGS:RAIN) dropped from Russe..
CI
2022Rain Therapeutics Inc.(NasdaqGS:RAIN) dropped from Russe..
CI
2022Rain Therapeutics Inc.(NasdaqGS:RAIN) dropped from Russe..
CI
2022Rain Therapeutics Inc.(NasdaqGS:RAIN) dropped from Russe..
CI
2022Rain Therapeutics Inc.(NasdaqGS:RAIN) dropped from Russe..
CI
2022Rain Therapeutics Inc.(NasdaqGS:RAIN) dropped from Russe..
CI
2022Rain Therapeutics Inc.(NasdaqGS:RAIN) dropped from Russe..
CI
2022Rain Therapeutics Inc.(NasdaqGS:RAIN) dropped from Russe..
CI
2022Rain Therapeutics Inc.(NasdaqGS:RAIN) dropped from Russe..
CI
2022Rain Therapeutics Inc.(NasdaqGS:RAIN) dropped from Russe..
CI
2022JonesTrading Initiates Rain Therapeutics at Buy With $17 Price Target
MT
2022Rain Therapeutics Inc.(NasdaqGS:RAIN) dropped from S&P G..
CI
2022Rain Therapeutics Inc. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
2022Roth Capital Starts Rain Therapeutics at Buy With $16 Price Target
MT
2022Piper Sandler Adjusts Rain Therapeutics' Price Target to $12 From $26, Maintains Overwe..
MT
2022Rain Therapeutics Files $250 Million Mixed Shelf
MT
2022Rain Therapeutics to Present on Milademetan at the 2022 American Society of Clinical On..
AQ
2022Transcript : Rain Therapeutics Inc., Q1 2022 Earnings Call, May 04, 2022
CI
2022RAIN THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
AQ
2022Rain Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2..
CI
1  2  3Next
Upcoming event on RAIN ONCOLOGY INC.